SCM
CBIO

Stonepine Capital Management’s Crescent Biopharma CBIO Stock Holding History

Stonepine Capital Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.56M Sell
85,000
-2,682
-3% -$30.8K 0.63% 27
2025
Q4 		$1.04M Buy
+87,682
New +$1.12M 0.76% 37

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Stonepine Capital Management's CBIO Position: Q1 2026 in Review

Stonepine Capital Management reduced its Crescent Biopharma (CBIO) stake by 3.1% in Q1 2026, selling an estimated $30.8K and leaving 85,000 shares worth $1.56M. The position accounts for 0.63% of the portfolio, ranked #27.

Stonepine Capital Management first reported a position in CBIO in Q4 2025 and has held it in 2 quarters since. 63 funds tracked by Wall St. Rank hold CBIO as of Q1 2026.

  • Stonepine Capital Management held 85,000 shares of Crescent Biopharma worth $1.56M as of Q1 2026.
  • Stonepine Capital Management sold 2,682 Crescent Biopharma shares in Q1 2026, an estimated $30.8K.
  • Crescent Biopharma made up 0.63% of Stonepine Capital Management's portfolio in Q1 2026, its #27 holding.
  • Stonepine Capital Management first reported a position in Crescent Biopharma in Q4 2025 and has held it in 2 quarters since.
  • 63 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.